0
November 6, 1972, Vol 222, No. 6 >
ARTICLE | November 6, 1972

Colestipol and Cholestyramine Resin: Title and subTitle BreakComparative Effects in Familial Type II Hyperlipoproteinemia FREE

Charles J. Glueck, MD; Starr Ford, Jr., MD; Deborah Scheel; Paula Steiner
[+] Author Affiliations

Reprint requests to 234 Goodman St, Cincinnati 45229 (Dr. Glueck).


JAMA. 1972;222(6):676-681. doi:10.1001/jama.1972.03210060032007
Text Size: A A A
Published online
Article
References

Two bile acid-sequestrant anion exchange resins, colestipol (U-26, 597A) and cholestyramine resin (Questran), were given in doses of 20 gm/day for four months each in a 14-month placebo crossover study to 25 patients with familial type II hyperlipoproteinemia. Plasma cholesterol and β-lipoprotein cholesterol were reduced to normal levels in 20 and 22 subjects, respectively, by one or both drugs. Coupled with low cholesterol, low saturated fat, polyunsaturate-rich diet, colestipol and cholestyramine provide parallel and alternative approaches to normalization of cholesterol and β-lipoprotein cholesterol in familial type II hyperlipoproteinemia.

REFERENCES

1 +
Hashim SA, VanItallie TB:  Cholestyramine resin therapy for hypercholesterolemia . JAMA 192:289-293, 1965;.
2 +
Fallon HJ, Woods JW:  Response of hyperlipoproteinemia to cholestyramine resin . JAMA 204:1161-1164, 1968;.
3 +
Howard AN, Hyams DE:  Combined use of Clofibrate and cholestyramine or DEAE Sephadex in hypercholesterolemia . Brit Med J 3:25-26, 1971;.
4 +
Levy RI, Fredrickson DS, Kwiterovich PO, et al:  Normalization of lipids in "Familial Hypercholesterolemia." Circulation 40( (suppl 3) ):15, 1969;.
5 +
Casdorph HR:  Treatment of the hyperlipidemic states with special emphasis on the place of cholestyramine in therapy . Angiology 21:654-660, 1970;.
6 +
Parkinson TM:  Hypolipidemic effects of orally administered dextran and cellulose anion exchangers in cockerels and dogs . J Lipid Res 8:24-29, 1967;.
7 +
Eastwood MA, Girdwood RH:  Lignin-A bile acid sequestrating agent . Lancet 2:1170-1172, 1968;.
8 +
Fahrenbach MJ, Riccardi BA, Grant WC:  Hypocholesterolemic activity of mucilaginous polysaccharides in white leghorn cockerels . Proc Soc Exp Biol 123:321-326, 1966;.
9 +
Parkinson TM, Gunderson K, Nelson NA:  Effects of colestipol (U-26,597A), a new bile acid sequestrant, on serum lipids in experimental animals and man . Atherosclerosis 11:531-537, 1970;.
10 +
Fredrickson DS, Levy RI, Lees RS:  Fat transport in lipoproteins: An integrated approach to mechanisms and disorders . New Eng J Med 276:32-44, 94-103, 148-156, 215-226, 273-281, 1967;.
11 +
Fredrickson DS, Levy RI, Lindgren FT:  A comparison of heritable abnormal lipoprotein patterns as defined by two different techniques . J Clin Invest 47:2446-2456, 1968;.
12 +
Kessler G, Leder H:  Fluorometric measurement of triglycerides , in Kress LT Jr (ed): Automation in Analytical Chemistry . New York, Mediad Inc, 1966;, p 341.
13 +
 Total cholesterol procedure, N-24 , in Auto-Analyzer Manual . Chauncey, NY, Technicon Instruments Corp, 1964;.
14 +
Fredrickson DS, Levy RI: Dietary management of hyperlipoproteinemia: Type II, publication 1667. Washington, DC, US Government Printing Office, 1969, p 395.
15 +
Choi Y, Kreines K:  Effect of glycodiazine on blood sugar in diabetes mellitus . Diabetes 17:507-512, 1968;.
16 +
Snedecor GW, Cochran WG:  Two-way analysis of variance , in Statistical Methods , ed 6. Ames, Iowa, Iowa State College Press, 1967;, pp 251, 299-338.
17 +
Gross L, Brotman M:  Hypoprothrombinemia and hemorrhage associated with cholestyramine therapy . Ann Intern Med 72:95-96, 1970;.
18 +
Goodman DS, Noble RP:  Turnover of plasma cholesterol in man . J Clin Invest 47:231-241, 1968;.
19 +
Moore RB, Crane CA, Frantz ID Jr.  Effect of cholestyramine on fecal excretion of intravenously administered cholesterol-4-14C and its degradation products in a hypercholesterolemic patient . J Clin Invest 47:1664-1671, 1968;.
20 +
Langer J, Strober W, Levy RI:  Familial Type II hyperlipoproteinemia: A defect of betalipoprotein apoprotein catabolism? J Clin Invest 48:49a, 1969;.
21 +
Cohen MI, Winslow PR, Boley SJ:  Intestinal obstruction associated with cholestyramine therapy . New Eng J Med 280:1285-1286, 1969;.
22 +
Danhof IE:  Effect of cholestyramine on fecal excretion of ingested radioiodinated lipids . Amer J Clin Nutr 18:343-349, 1966;.
23 +
Gallo DG, Bailey KR, Sheffner AL:  The interaction between cholestyramine and drugs . Proc Soc Exp Biol Med 120:60-65, 1965;.
24 +
Northcutt RC, Stiel JN, Hollifield JW, et al:  The influence of cholestyramine on thyroxine absorption . JAMA 208:1857-1861, 1969;.
25 +
Weizel A, Estrich DL, Splitter SD, et al:  Cholestyramine effect on plasma triglycerides in normolipidemic patients . Proc Soc Exp Biol Med 130:149-150, 1969;.
26 +
Jones RJ, Dobrilovic L:  Lipoprotein lipid alterations with cholestyramine administration . J Lab Clin Med 75:953-967, 1970;.
27 +
Slack J:  Risks of ischaemic heart-disease in familial hyperlipoproteinemic states . Lancet 2:1380-1382, 1969;.
28 +
Quintao E, Grundy SM, Ahrens EH Jr.  Effects of dietary cholesterol on the regulation of total body cholesterol in man . J Lipid Res 12:233-247, 1971;.

Figures

Tables

Interactive Graphics

Video

Country-Specific Mortality and Growth Failure in Infancy and Yound Children and Association With Material Stature

Use interactive graphics and maps to view and sort country-specific infant and early dhildhood mortality and growth failure data and their association with maternal

1 +
Hashim SA, VanItallie TB:  Cholestyramine resin therapy for hypercholesterolemia . JAMA 192:289-293, 1965;.
2 +
Fallon HJ, Woods JW:  Response of hyperlipoproteinemia to cholestyramine resin . JAMA 204:1161-1164, 1968;.
3 +
Howard AN, Hyams DE:  Combined use of Clofibrate and cholestyramine or DEAE Sephadex in hypercholesterolemia . Brit Med J 3:25-26, 1971;.
4 +
Levy RI, Fredrickson DS, Kwiterovich PO, et al:  Normalization of lipids in "Familial Hypercholesterolemia." Circulation 40( (suppl 3) ):15, 1969;.
5 +
Casdorph HR:  Treatment of the hyperlipidemic states with special emphasis on the place of cholestyramine in therapy . Angiology 21:654-660, 1970;.
6 +
Parkinson TM:  Hypolipidemic effects of orally administered dextran and cellulose anion exchangers in cockerels and dogs . J Lipid Res 8:24-29, 1967;.
7 +
Eastwood MA, Girdwood RH:  Lignin-A bile acid sequestrating agent . Lancet 2:1170-1172, 1968;.
8 +
Fahrenbach MJ, Riccardi BA, Grant WC:  Hypocholesterolemic activity of mucilaginous polysaccharides in white leghorn cockerels . Proc Soc Exp Biol 123:321-326, 1966;.
9 +
Parkinson TM, Gunderson K, Nelson NA:  Effects of colestipol (U-26,597A), a new bile acid sequestrant, on serum lipids in experimental animals and man . Atherosclerosis 11:531-537, 1970;.
10 +
Fredrickson DS, Levy RI, Lees RS:  Fat transport in lipoproteins: An integrated approach to mechanisms and disorders . New Eng J Med 276:32-44, 94-103, 148-156, 215-226, 273-281, 1967;.
11 +
Fredrickson DS, Levy RI, Lindgren FT:  A comparison of heritable abnormal lipoprotein patterns as defined by two different techniques . J Clin Invest 47:2446-2456, 1968;.
12 +
Kessler G, Leder H:  Fluorometric measurement of triglycerides , in Kress LT Jr (ed): Automation in Analytical Chemistry . New York, Mediad Inc, 1966;, p 341.
13 +
 Total cholesterol procedure, N-24 , in Auto-Analyzer Manual . Chauncey, NY, Technicon Instruments Corp, 1964;.
14 +
Fredrickson DS, Levy RI: Dietary management of hyperlipoproteinemia: Type II, publication 1667. Washington, DC, US Government Printing Office, 1969, p 395.
15 +
Choi Y, Kreines K:  Effect of glycodiazine on blood sugar in diabetes mellitus . Diabetes 17:507-512, 1968;.
16 +
Snedecor GW, Cochran WG:  Two-way analysis of variance , in Statistical Methods , ed 6. Ames, Iowa, Iowa State College Press, 1967;, pp 251, 299-338.
17 +
Gross L, Brotman M:  Hypoprothrombinemia and hemorrhage associated with cholestyramine therapy . Ann Intern Med 72:95-96, 1970;.
18 +
Goodman DS, Noble RP:  Turnover of plasma cholesterol in man . J Clin Invest 47:231-241, 1968;.
19 +
Moore RB, Crane CA, Frantz ID Jr.  Effect of cholestyramine on fecal excretion of intravenously administered cholesterol-4-14C and its degradation products in a hypercholesterolemic patient . J Clin Invest 47:1664-1671, 1968;.
20 +
Langer J, Strober W, Levy RI:  Familial Type II hyperlipoproteinemia: A defect of betalipoprotein apoprotein catabolism? J Clin Invest 48:49a, 1969;.
21 +
Cohen MI, Winslow PR, Boley SJ:  Intestinal obstruction associated with cholestyramine therapy . New Eng J Med 280:1285-1286, 1969;.
22 +
Danhof IE:  Effect of cholestyramine on fecal excretion of ingested radioiodinated lipids . Amer J Clin Nutr 18:343-349, 1966;.
23 +
Gallo DG, Bailey KR, Sheffner AL:  The interaction between cholestyramine and drugs . Proc Soc Exp Biol Med 120:60-65, 1965;.
24 +
Northcutt RC, Stiel JN, Hollifield JW, et al:  The influence of cholestyramine on thyroxine absorption . JAMA 208:1857-1861, 1969;.
25 +
Weizel A, Estrich DL, Splitter SD, et al:  Cholestyramine effect on plasma triglycerides in normolipidemic patients . Proc Soc Exp Biol Med 130:149-150, 1969;.
26 +
Jones RJ, Dobrilovic L:  Lipoprotein lipid alterations with cholestyramine administration . J Lab Clin Med 75:953-967, 1970;.
27 +
Slack J:  Risks of ischaemic heart-disease in familial hyperlipoproteinemic states . Lancet 2:1380-1382, 1969;.
28 +
Quintao E, Grundy SM, Ahrens EH Jr.  Effects of dietary cholesterol on the regulation of total body cholesterol in man . J Lipid Res 12:233-247, 1971;.

Letters

Submit a Letter
CME Course for:


You need to register in order to view this quiz.


To understand the clinical management of acute heart failure syndromes.
Accreditation Information The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
To view and print your certificate and access a summary of your CME courses go to My CME.
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s “Cited By” API will populate this tab (http://www.crossref.org/citedby.html).
Compression-Only CPR: Pushing the Science Forward
Cone
AAM 2010;304:1493-1495.
All you need to read in the other general journals
BMJ 2010;341:c5893-c1494.
Submit a Response

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

© 2012 American Medical Association. All Rights Reserved.
Powered bySilverchair Information Systems